

# DORSET MEDICINES ADVISORY GROUP

## Recommendation Summary



**Dorset  
Clinical Commissioning Group**

**The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the Clinical Commissioning Group (CCG). It advises the system on prescribing and commissioning of medicines in Dorset.**

Summary of recommendations made by the group in March/April 2020. Formulary entries and associated documents can be accessed at [www.dorsetformulary.nhs.uk](http://www.dorsetformulary.nhs.uk). Due to the COVID-19 pandemic these recommendations have been made following circulation of the documents to DMAG members, for feedback virtually.

PRODUCT	DECISION		COMMENTS
<b>1. Products re-categorised</b>	<b>Previous position</b>	<b>Recommended position</b>	
Abstral® sublingual tablets	Red	Amber	DMAG approved for use in <b>palliative care only</b> , as a second line option for management of breakthrough pain in adults using opioid therapy for chronic cancer pain
<b>2. New requests</b>			
Lusutrombopag	Red		In line with <a href="#">NICE TA617</a> as an option for treating severe Thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.
Patiromer	Red		In line with <a href="#">NICE TA623</a> for treating Hyperkalaemia
<b>3. Products considered by NICE</b>			
<a href="#">NICE TA617</a> Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure <a href="#">NICE TA623</a> Patiromer for treating Hyperkalaemia			

PRODUCT	DECISION	COMMENTS
<b>4. Miscellaneous recommendations by DMAG</b>		
NICE COVID-19 Guidelines		NICE is publishing a series of rapid guidelines and evidence summaries to support the care of patients during the current pandemic. DMAG support the use of these guidelines. Available at: <a href="https://www.nice.org.uk/guidance/published?type=cov,coa">https://www.nice.org.uk/guidance/published?type=cov,coa</a>
<b>5. Further Assessment / Evidence Required</b>		
N/A		
<b>6. New documents approved</b>		
<p>Shared Care Guideline for Immediate release fentanyl sublingual tablets (Abstral®) in adults with breakthrough pain (PALLIATIVE CARE ONLY)</p> <p>Commissioning Statement on the use of Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (NICE TA617)</p> <p>Commissioning Statement on the use of Patiromer for treating Hyperkalaemia (NICE TA623)</p>		
<b>7. Documents Reviewed</b>		
<p>Commissioning statement on the use of immediate release (transmucosal) fentanyl products updated.</p> <p>To demonstrate only Abstral® is commissioned for use in Dorset, no other formulations are approved for use in Dorset in accordance with NHS England guidance: <a href="https://www.england.nhs.uk/wp-content/uploads/2019/08/items-which-should-not-routinely-be-prescribed-in-primary-care-v2.1.pdf">https://www.england.nhs.uk/wp-content/uploads/2019/08/items-which-should-not-routinely-be-prescribed-in-primary-care-v2.1.pdf</a>.</p>		

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset